CDIO
Cardio DiagnosticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
If reimbursement/billing access improves and the company shows repeatable test volume from its CLIA lab and partnerships, the current microcap base could re-rate from a financing story toward an execution story.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
CLIA lab execution and partnership conversion risk remain high for a microcap health-tech issuer.
Momentum
100
Value
59
Sentiment
23
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.90 · Bull $3.00 · Bear $0.70
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-29 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $2.00
Why
Momentum100 · Δ7d -
Value59 · Δ7d +0.6
Sentiment23 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
100
34% active weight
Current posture
7d trendFlat
Δ7d
-
Δ21d
-
Value
59
32% active weight
Current posture
7d trendFlat
Δ7d
+0.6
Δ21d
+0.4
Sentiment
23
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade B. Momentum 99.9 / Value 58.9 / Sentiment 23.2
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$6.3M
Beta
2.89
Shares Out
1.83M
P/E (TTM) · Derived
-0.4
P/S (TTM)
344.63
P/FCF (TTM) · Derived
-0.91
Rev YoY
-56.5%
EPS YoY
+43.7%
Gross Margin
-
Op Margin
-41401.1%
Net Debt
-$7.52M
Current Ratio
17.39
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology